NYBA
New York Biotechnology Association
 
 
More...
NYBA: Archived News
NYBA News | Member News | Press Release
 
News type
OSI Pharmaceuticals Inc.
Headline: Data From The Phase III ATLAS Study Show Tarceva In Combination With Avastin As First-Line
Maintenance Therapy Improved Progression-Free Survival In A
Date: 30-May-2009
News Type: Member News
Data from the Phase III ATLAS Study Show Tarceva in Combination with Avastin as First-Line Maintenance Therapy Improved Progression-Free Survival in Advanced Lung Cancer -- Study is Second Positive Phase III Trial of Tarceva as First-Line Maintenance Therapy -- ORLANDO, Fla., May 30, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced...
Details »
 
Pfizer Inc.
Headline: New Pfizer Data Helps To Identify Kidney Cancer Patients Who May Be Most Likely To Benefit
From Treatment
Date: 29-May-2009
News Type: Member News
New Pfizer Data Helps to Identify Kidney Cancer Patients Who May Be Most Likely to Benefit from Treatment Anti-tumor Activity Also Shown in Prostate Cancer Patients Treated with Sutent ORLANDO, Fla.--(BUSINESS WIRE)--Pfizer announced today, at the 45th American Society of Clinical Oncology (ASCO) Annual Meeting, the results of several clinical studies tha...
Details »
 
Genentech Inc.
Headline: Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival In Advanced
Breast Cancer
Date: 29-May-2009
News Type: Member News
Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival in Advanced Breast Cancer -- Data From RIBBON 1 Study Provides Efficacy and Safety Information With Different Types of Chemotherapy  -- Orlando, Fla. --  May 29, 2009 --  Genentech, Inc. today announced results of a Phase III study (RIBBON 1) that showed Avastin® (bevac...
Details »
 
Applied DNA Sciences, Inc.
Headline: Applied DNA Sciences Uses DNA Authentication To Safeguard Premium Wines Against
Counterfeiting And Fraud
Date: 28-May-2009
News Type: Member News
Applied DNA Sciences, Inc. (OTC Bulletin Board: APDN), a provider of DNA-based security solutions, announced today that it is using its patented and proprietary DNA authentication to help premium wine producers in their fight against fraud and counterfeiting. With counterfeit wines estimated to account for as much as five percent of the secondary market (Wine Spectat...
Details »
 
OSI Pharmaceuticals Inc.
Headline: Phase 3 Trial Initiated To Evaluate Combination Therapy Of Nexavar(R) And Tarceva(R) In
Patients With Liver Cancer
Date: 28-May-2009
News Type: Member News
Bayer HealthCare LLC., Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX), OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) and Roche today announced the initiation of a Phase 3 trial examining Nexavar(R) (sorafenib) tablets in combination with Tarceva(R) (erlotinib) tablets as a potential new treatment option for patients with advanced hepatocellular carcinoma (HCC), or primary liver cancer. Th...
Details »
 
Bristol-Myers Squibb Company
Headline: First Phase III Data On Innovative Compound For Solid Organ Transplantation To Be Featured
At American Transplant Congress
Date: 28-May-2009
News Type: Member News
Nine Clinical Presentations to Highlight Belatacept American Transplant Congress NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that belatacept, an investigational co-stimulation blocker being studied for use in solid organ transplantation, will be the subject of nine company-sponsored cli...
Details »
 
Kinex Pharmaceuticals
Headline: Kinex Pharmaceuticals Will Present Results From A Phase 1 Clinical Study With KX2-391
Date: 27-May-2009
News Type: Member News
Kinex Pharmaceuticals will present results from a Phase 1 clinical study with KX2-391, at the ASCO 2009 Annual Meeting in Orlando, on May 29, 2009.  The study was carried out at MD Anderson, Roswell Park Cancer Institute (RPCI) and Fox Chase Cancer Center.  Dr. Alex Adjei, the Principal Investigator from RPCI will deliver the presentation entitled “Results of a phase I trial of...
Details »
 
Amgen, Inc.
Headline: New Survey Highlights Growing Concern About Risk Of Infection In Cancer Patients And
Emerging Antibiotic Resistance
Date: 27-May-2009
News Type: Member News
--Amgen, CDC Foundation and CDC Partner to Launch Three-Year Initiative to Improve Infection Control in Vulnerable Cancer Patient Population  -- Amgen (Nasdaq: AMGN) today announced the results of a national Harris Interactive, Inc. survey indicating that the vast majority of oncologists and infectious disease (ID) specialists are highly concerned about the negative impact...
Details »
 
Bristol-Myers Squibb Company
Headline: FDA Grants Full Approval For SPRYCEL® (dasatinib) For The Treatment Of Adults With
Chronic Myeloid Leukemia Who Are Resistant Or Intolerant To Prior T
Date: 26-May-2009
News Type: Member News
FDA Grants Full Approval for SPRYCEL® (dasatinib) for the Treatment of Adults with Chronic Myeloid Leukemia Who Are Resistant or Intolerant to Prior Therapies Including Gleevec®* Two-Year Follow-Up Data Includes 80 Percent Progression-Free Survival Rate in Gleevec-Resistant or Intolerant Patients with Chronic Phase CML NEW YORK--(BUSINESS WIRE)--B...
Details »
 
Applied DNA Sciences, Inc.
Headline: Applied DNA Sciences Presents Layered Security Solutions For Sustainable, Green,
Affordable Packaging At IOPP Summit
Date: 26-May-2009
News Type: Member News
Applied DNA Sciences Presents Layered Security Solutions for Sustainable, Green, Affordable Packaging at IOPP Summit STONY BROOK, N.Y., May 26, 2009 /Market Wire/ -- Applied DNA Sciences, Inc. (OTC Bulletin Board: APDN), a provider of DNA-based security solutions, has developed sustainable, “green” and affordable layered security solutions for pr...
Details »
 
« Previous Next »
   
  © 2008 New York Biotechnology Association HOME | ABOUT NYBA | CONTACT US | SITE MAP Website by Axxiem